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Abstract
Background: The ability to share human biological samples, associated data and results across disease-specific and
population-based human research biobanks is becoming increasingly important for research into disease
development and translation. Although informed consent often does not anticipate such cross-domain sharing, it is
important to examine its plausibility. The purpose of this study was to explore the feasibility of bridging consent
between disease-specific and population-based research. Comparative analyses of 1) current ethical and legal
frameworks governing consent and 2) informed consent models found in disease-specific and population-based
research were conducted.
Discussion: Ethical and legal frameworks governing consent dissuade cross-domain data sharing. Paradoxically,
analysis of consent models for disease-specific and population-based research reveals such a high degree of
similarity that bridging consent could be possible if additional information regarding bridging was incorporated
into consent forms. We submit that bridging of consent could be supported if current trends endorsing a new
interpretation of consent are adopted. To illustrate this we sketch potential bridging consent scenarios.
Summary: A bridging consent, respectful of the spirit of initial consent, is feasible and would require only small
changes to the content of consents currently being used. Under a bridging consent approach, the initial data and
samples collection can serve an identified research project as well as contribute to the creation of a resource for a
range of other projects.
Background
Millions of human biological samples and associated
health data are stored in research biobanks and consti-
tute essential resources for biomedical researchers inter-
ested in accessing large and valuable datasets needed to
study complex disease aetiology, improve diagnostics,
and advance the agenda of personalized medicine. The
ability to share and combine data from disease-specific
and population-based research has become increasingly
important for translational medicine. For instance,
research designs that recruit by genotype rather than by
illness outcome [1] are becoming more common and
will also be a fruitful approach for studying pathways to
disease where variation along the continuum from pre-
disease status to clinical manifestation is analyzed. Such
study designs will entail extensive cross-domain data
sharing between disease-specific and population-based
research. However, cross-domain data sharing between
these different research environments remains limited,
partly because such sharing is not anticipated in most
traditional consent forms. This is particularly true in
disease-specific clinical research settings where informed
consent traditionally is targeted to research purposes
related to a specific disease and does not anticipate or
accommodate future research aims that could be
addressed with the data [2,3]. In this paper, we investi-
gate whether it is possible and feasible to bridge con-
sent, that is to formulate consent models that include
the necessary core elements for each research domain
and simultaneously anticipate cross-domain data
sharing.
To investigate this, we conduct two sets of compara-
tive analyses that focus on: 1) current ethical and legal
frameworks governing consent with regards to potential
hindrances and opportunities for cross-domain sharing,
and 2) current consent models found in disease-specific
and population-based research. The purpose of this
work is to identify potential hindrances and opportu-
nities to bridge consent and to propose practical solu-
tions to bridging consent that dovetail with the new
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For the purpose of this study, we identified three sepa-
rate domains of research across which data sharing
would be valuable: 1) Disease Specific Biobank Research
(DSBR) refers to research typically conducted by large
research consortia outside of a clinical setting using a
collection of human biological material and associated
information stored for research on a pre-determined set
of diseases; 2) Disease Specific Clinical Research (DSCR)
refers to clinically-based research conducted in associa-
tion with a biobank to evaluate the effectiveness and
safety of medications or medical devices (e.g. clinical
trials); 3) Population Biobank Research (PBR) refers to
research conducted on populations unselected with
respect to a particular disease using human biological
material and associated information stored for future
unspecified research.
First, a comparative analysis of relevant ethical and
legal frameworks governing consent in biobanking was
conducted with regards to identifying potential hin-
drances and opportunities for cross-domain sharing.
Regulatory consent requirements regarding the content
of consent forms were not analysed as each country has
different ethical and legal norms. Relevant international
documents and guidelines were identified with the
HumGen International database [4] and official websites
of the Council of Europe [5]. Variations of the following
keywords were used to guide our searches, either alone
or in conjunction: [’research’]a n d / o r[ ’samples’ and/or
‘data’ and/or ‘information’]a n d / o r[ ’consent’]a n d / o r
[’genetics’ and/or ‘medical’ and/or ‘health’]a n d / o r[ ’bio-
bank’ and/or ‘hospital’ and/or ‘repository’ and/or ‘file’].
This review is based upon documents written in or
translated into English or French, before March 1st,
2011.
Next, to examine the feasibility of bridging consent, a
comparative analysis of consents in the three research
environments was conducted. To do so, three sources of
information were examined: 1) consent forms referred
to as consent models and made publicly available by
international organisations and research consortia, 2)
consent models proposed in the literature, and 3) ele-
ments of consent recommended in guidelines from
international organisations and councils. An internet
search was conducted to identify the information in
point 1 and 3 above by using the following key words:
[’informed’]a n d[ ’consent’]a n d[ ’model’ and/or ‘tem-
plate’]. A similar search was made in Pubmed to identify
models of consent form proposed in the literature. The
criteria used to select the consent requirements were
that the consent models or recommended elements of
consent were developed by organisations and research
consortia that are representative of their research
d o m a i nd u et ot h e i rs i z e ,i n t e r n a t i o n a lp r o f i l ea n d
recognition or that they were developed through
research analyzing informed consent materials used in a
specific research domain [6-22]. Our comparative analy-
sis identified 1) core elements in the structure of the
consents, and 2) similarities and differences in the infor-
mation content of consents.
Discussion
Results from the comparative analysis of ethical and legal
frameworks governing consent
The results, based upon a comparative analysis of
whether ethical and legal frameworks governing consent
provide opportunities for bridging, show that the brid-
ging of consent between different research domains is
not specifically addressed. Consent to research is based
on an extensive set of international and national ethics
guidelines which have always required the respect for
the autonomy of research participants via a free and
informed consent. Classical informed consent requires
the appropriate disclosure of the specific research objec-
tives, procedures, risks, and benefits to participants
[7,8,22-28]. The use of biological samples and data out-
side the range of the research of the consent form
would in these guidelines be considered a ‘secondary
use’, which is neither legal nor ethical in most jurisdic-
tions, in the absence of a new consent, an ethics waiver,
or legal provisions [29]. Therefore, the use of already
collected samples and data in different research domains
appears to be nearly impossible.
Our analysis identified one exception to this restrictive
view of consent. In 1995, the Human Genome Organi-
zation’s Ethics Committee stated, in the Statement on
Human Genomic Databases [30], that the choices of
individuals should be respected, informed consent may
include notification of uses (actual or future) or opting
out, and mechanisms should be established to ensure
respect for such choices. This statement indicates the
possibility to share a participant’s samples, data, and
results from one research setting to another, as long as
the choices expressed by the participant in the initial
research are respected. This guideline is the first step
into a paradigm shift towards a more flexible interpreta-
tion of consent. Such paradigm shift is necessary to
allow the bridging of consents which, on the surface,
would not allow uses of samples or data in other
research domains. Therefore, in order to respect the
choices expressed in the initial consent, it could be
assumed that a research participant would agree to
allow his/her samples, associated data, and results to be
accessed for other research in different research
domains, provided that the new research focuses on the
same diseases or a more restrictive set of diseases than
the initial research.
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The results of our comparative analysis of consent mod-
els across the three different research domains (DSBR,
DSCR and PBR) reveals considerable congruence regard-
ing consent requirements. The models for all three
domains share the same consent structure comprised of
15 core elements. This similarity most likely arises
because informed consent models used in DSBR and
PBR are derived from those used in DSCR [14] and
because protection of the participant rights is the funda-
mental concern of all consents. Our analysis also shows
that the nature of the information provided to research
participants under each core element is highly similar
(See Table 1 - Differences and Similarities in Informed
Consent Requirements in DSBR, DSCR and PBR). How-
ever, differences exist in terms of length, scope and level
of detail of the information provided in the consents as
described in more detail below. Elements of consent in
which no differences could be identified are not listed.
Invitation, presentation of the study and voluntary
participation
In the research settings studied the consent forms begin
with an invitation to participants and a brief presenta-
tion of the research (study’s title, name and affiliation of
the principal investigator and co-investigators). Informa-
tion about the voluntary nature of participation in the
research is usually provided. However, informed consent
models for DSCR emphasize the specific research goals
of the study in their introductory information (i.e. trial
of a new treatment for breast cancer) while models in
DSBR and PBR, where the research goals are broader (i.
e. cancer research or research on common diseases
affecting populations) focus more on explaining that the
data and samples collected will be used for research
related to a specified disease or group of diseases.
Research protocols
Consent forms in the three research settings describe
the research protocol, including the type of samples and
data to be collected, the nature of the interventions (if
any), the duration and timetable of the study, and cir-
cumstances under which early termination may occur. If
the original research setting is clinical research, this sec-
tion also provides information about the clinical proce-
dures and randomization. Procedures are widely
described in DSCR while they are less described in
DSBR and PBR where it is more typical to find general
descriptions regarding the type of data and samples that
will be collected and regarding re-contact procedures
that may be necessary during the conduct of the study.
Risks
In all consent forms the section on risks describes
known and anticipated physical, psychological and infor-
mational risks related to participation in the study. Pro-
cedures that will be undertaken if risks materialize are
also described. Models in DSCR place emphasis on the
physical and psychological risks for the participant and
their relatives while models in DSBR and PBR place
emphasis on informational risks (e.g. risks associated
with breaches of confidentiality). Potential group harm
in the event of breaches of confidentiality is only men-
tioned in PBR.
Benefits
Consents under all three research settings include infor-
mation about the expected direct and indirect benefits
for the participants, the local community and the
broader scientific community. DSCR emphasizes direct
benefits to the research participants while DSBR and
PBR emphasize indirect benefits to larger groups and
highlight the scientific relevance of biobanks.
Financial compensation, indemnification and costs
Consent forms in all three research settings provide
information about costs related to participation in the
study and financial compensation (if any) offered to the
participants. In DSCR, information about treatment
costs and research-related i n j u r yc o s t si sp r o v i d e d ,
which is not the case in DSBR and PBR.
Confidentiality
Consent forms in all three research settings describe
procedures ensuring the protection and security of data
and samples, the privacy of research participants and
the confidentiality of their data. These procedures are
briefly mentioned in DSCR while they are described in
more depth in DSBR and PBR where e.g. the risk for re-
identification is mentioned as a potential issue.
Data access and data sharing
All three research domains provide information regard-
ing conditions and procedures for internal and external
sharing of data, samples and results. DSCR emphasizes
informing research participants about data sharing
restrictions. Data sharing for future research with other
researchers is usually not mentioned. In contrast, data
sharing procedures are widely described in DSBR and
PBR. It should be noted that it is only in PBR that infor-
mation is given about the requirement to return samples
and research results to the biobank from which they
originate.
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Element 1 Invitation, presentation of the study and voluntary participation
Similarities Study title and location
Names and affiliations of principal investigators and co-investigators
Study type, purposes and justification
Criteria for participant selection and estimated number of participants
Sources and duration of funding
Voluntary participation
Differences Found in DSCR, not in DSBR and PBR
Description of clinical trial
Reasons for testing
Current experience with drug/device
Availability of products and interventions resulting from the research
Element 2 Research protocols
Similarities Duration and timetable of the study
Procedures (physical exams, clinical measurements, samples intake, number of visits, interventions)
Types of data and samples to be collected
Differences Found in DSCR, not in DSBR and PBR
Description of routine, experimental clinical procedures (randomization, blinding, placebo use, biopsy, surgery, etc.)
Expected duration of participation in the study
Circumstances of early termination
Found in DSBR and PBR, not in DSCR
Re-contact procedures
Element 3 Risks
Similarities Known and anticipated physical, emotional and psychological risks and discomforts
Known and anticipated risks associated with breaches of confidentiality
Medical procedures in the event of harm or in the need of treatment of research-related injuries
Differences Found in PBR, not in DSCR and DSBR
Risks of potential group stigmatization
Element 4 Benefits
Similarities Expected direct and indirect benefits to participants, local community and broader scientific community
Information about return of personal or financial benefits to participants (if any)
Differences Found in PBR, not in DSCR and DSBR
Scientific importance of biobanks for the public good
Element 5 Financial compensation, indemnification and costs
Similarities Procedures for incentives and financial compensations
Differences Found in DSCR, not in DSBR and PBR
Costs in case of treatment of research-related injuries
Costs related to participation in research
Element 6 Confidentiality
Similarities Procedures for data protection and maintenance
Limits to confidentiality protection
Differences Found in DSBR and PBR, not in DSCR
Prohibition of data re-identification
Element 7 Data access and data sharing
Similarities Conditions and procedures for internal and external access to data, biological samples and health records (e.g. by researchers,
participants or regulatory bodies)
Conditions for secondary or future uses of data and biological samples within the same research area
Differences Found in DSCR, not in DSBR and PBR
Participant’s right to place restrictions on specific future uses of data and biological samples
Found in PBR, not in DSCR and DSBR
Requirements for return of samples and research results to the biobank
Element 8 Storage
Similarities Procedures for storage and destruction of data and samples, also in the case of participant withdrawal
Differences Found in PBR, not in DSCR and DSBR
Procedures for use of data and samples after donor’s death
Rules regulating the use of data and samples in case of biobank or owner/custodian surrender
Element 9 Return of results
Similarities Procedures for individual return of results to participants/medical records during or after the research
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All three research domains provide information about
data and sample retention, storage and destruction (also
in the case of participant withdrawal) although it is
more comprehensive in DSBR and particularly in PBR
where information about the fate of the data and sam-
ples in the event of donor’s death or biobank disman-
tling is provided.
Return of results
All three research settings provide information about
procedures for feedback of general and/or individual
results during and after the study (if any) and the
inclusion of study results in the medical record. Over-
all strategies for communication with participants and
society are also described. While procedures for indivi-
dual feedback of results are usually described in details
in DSCR, they are described in shorter terms in DSBR
and PBR where individual return of results are either
not practised or practised restrictively (e.g. only clinical
measurements are returned).
Commercialization
All three research domains provide information about
samples not being used for commercial purposes, poten-
tial third-part commercialization and policies of no
return of financial benefits to research participants. The
issue of sample ownership is addressed in DSBR while it
is not mentioned in DSCR and PBR.
Right to withdraw
Information about the right to withdraw remains uni-
form through all three research domains although more
detailed information about e.g. the fate of data and sam-
ples in the case of participant withdrawal is provided in
PBR.
Table 1 Differences and Similarities in Informed Consent Requirements in DSBR, DSCR and PBR (Continued)
Differences Found in DSBR and PBR, not in DSCR
Procedures for return of general results by means of a Newsletter, web site etc.
Element
10
Commercialization
Similarities Prohibition of samples commercialization
Potential for third-part commercialization of products resulting from the research
Non return of financial benefits to the participants
Differences Found in DSBR, not in DSCR and PBR
Rules for ownership of samples
Element
11
Right to withdraw
Similarities Participant’s right to withdraw at any time without penalty or loss of benefits
Differences Found in DSCR, not in DSBR and PBR
Alternatives to participation
Description of established standard treatments
Found in DSBR and PBR, not in DSCR
Placement of data in open or controlled databases
Impossibility to withdraw data already contained in analyses
Element
12
Re-contact
Similarities Re-contact procedures (e.g. frequency, method) if any
Differences Found in DSBR and PBR, not in DSCR
Re-contact procedures for new unanticipated research uses
Element
13
Contact information
Similarities Contact information for principal investigators, co-investigators and sponsoring institutions
Contact information for the Institutional Review Board which granted approval
Element
14
Ethics oversight
Similarities Information about procedures for ethics oversight of current project
Differences Found in DSBR and PBR, not in DSCR
Information about procedures for ethics oversight of future projects
Element
15
Signatures
Similarities Signatures of participant, witness (if the participant is illiterate), principal investigators and translator (if needed)
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Disease Specific Biobank Research and Disease Specific Clinical Research
Element 1 Invitation, presentation of the study and voluntary participation
Scientific relevance of biobanks
Importance for research
Data and samples use for other related conditions or in other research settings (such as disease specific biobanks)
Element 2 Research protocols
No additional elements required
Element 3 Risks
No additional risks, except related to expansion of scope of research
Element 4 Benefits
Expected benefits related to the use of data and samples for other related conditions or other research settings
(such as disease specific biobanks)
Element 5 Financial compensation, indemnification and costs
No additional elements required
Element 6 Confidentiality
No additional confidentiality issues, except related to expansion of scope of research (data storage/retention)
Element 7 Data Access and data sharing
Access procedures to data, samples and results by other research settings
Return of new data, samples and results from the other research settings to the original research setting
The participant’s right to agree/disagree to access to their data and samples for other related conditions or other
research settings (such as disease specific biobanks)
Element 8 Storage
Rules related to the use, retention, storage and destruction of data and samples for other related conditions or other
research settings (such as disease specific biobanks)
Element 9 Return of results
Return of results for research performed in other related conditions or other research settings (such as disease
specific biobanks); (return to the original research setting, general vs. individual, return to the participant (or not),
etc.)
Element 10 Commercialization
Potential commercialization and possible patenting of study related tests, drugs, devices, etc. in other research or
settings
Element 11 Right to withdraw
Creation of a uniform process for withdrawal
Element 12 Re-contact
Re-contact for use of samples, data and results in other research settings (such as disease specific research projects or
other disease specific biobanks or population biobanks)
Creation of a uniform process to ensure that the re-contact procedure is respected in every research setting
Element 13 Contact information
Contact information for principal investigator, co-investigators, sponsoring institutions (when applicable) and the
Institutional Review Board in other research settings
Element 14 Ethics oversight
Information about the extent of ethics oversight and approval mechanisms for the use of the data, samples and
results of this study in other research settings
Element 15 Additional choices and signatures
Disease Specific Biobank
Research
Add:
I agree that the samples and data collected during [name of the study], be used in other research settings, for
research on [name of the disease] and related conditions or included in [name of disease specific biobank]. YES/NO
Disease Specific Clinical
Research
Add:
I agree that the samples and data collected during [name of the study], be used for research on [name of the disease]
and related conditions or included in [name of disease specific biobank]. YES/NO
No additional elements are required for Population Biobank Research.
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Consent forms in all three research settings inform par-
ticipants about re-contact procedures when investigators
for instance need to collect additional data or obtain
authorization to conduct new research on the data and
samples collected. Re-contact procedures for new unan-
ticipated research uses are only mentioned in DSBR and
PBR.
Ethics oversight
Information about procedures for ethics oversight is
provided in all three types of research although ethics
oversight of future projects is only mentioned in DSBR
and PBR.
Summary
We analyzed the feasibility of bridging consent between
disease-specific and population-based research. The
results of our comparative analysis of ethical and legal
frameworks governing consent show that the current
interpretation of consent in existing international and
national ethics guidelines does not facilitate data sharing
in general. Paradoxically, the results of our comparative
analysis of actual consent requirements reveal no signifi-
cant differences across the research domains studied.
Following in the footsteps of the Human Genome Orga-
nization’s Ethics Committee, the adoption of a new
interpretation of consent, based on the spirit of the
initial consent given by the participant, would facilitate
cross-domain data sharing though the bridging of con-
sent across research domains. Such bridging would be
possible as long as the choices expressed by the partici-
pant in the initial research are respected. It could for
instance be assumed that a research participant would
agree to allow his/her samples, associated data, and
results to be accessed for other research, in different
research domains, provided that the new research
focuses on the same diseases or a subset thereof, stipu-
lated in the initial research. In the future, attention may
shift away from disease endpoints as more focus is
placed on pathways to disease [31]. However, as long as
international guidelines require research subjects to be
informed of the disease or set of diseases under study, it
seems ethically hazardous to overly stretch an already
restricted consent. Therefore, where initial consent is
restricted to a specific disease, we propose that bridging
i sp o s s i b l eo n l yw i t ho t h e rsimilar disease specific
research (which would then be considered as a primary
use of data and samples, and not a secondary use).
Our analysis of the literature and consent forms
demonstrates that most consent forms could be used as
the basis for a bridging consent. To allow bridging, addi-
tional information should be included under each core
element of consent as described in Table 2 (Proposed
Modifications that Enable Bridging Consent) to support
data sharing and unspecified secondary uses of the data,
the samples and the research results. Bridging consent is
not expected to significantly increase the length of most
of the restrictive consent forms as it requires the inclu-
sion of only a few additional elements of information
such as for example concerning sample or data sharing.
It should be noted that bridging consent does not alter
the requirement to obtain REB review for new research
involving human subjects, data or tissues.
Bridging consent requires that the responsibilities
between the original data collectors and future users of
the data be clearly outlined, regarding sharing, mainte-
nance and protection of data. Procedures for the protec-
tion of privacy, protection of the participant’sr i g h tt o
withdraw and return of results should also be shared
between the original data collectors and future users,
and clear guidelines should be established. Many of
these challenges are already being addressed through
ELSI harmonization initiatives aiming to implement data
sharing codes of conduct and policies [32] and are
encouraged by empirical studies indicating that research
participants generally support wide data sharing for
research purposes given that privacy and confidentially
concerns are appropriately handled and secured [33-35].
Bridging consent has many advantages. First, it allows
consent to evolve in pace with biomedical science. For
many studies in bioscience today the traditional distinc-
tion between clinical and non-clinical data is becoming
less relevant and it is important that the ethics-based
structures put in place to support contemporary
research keep apace with the changing nature of the
science. Second, bridging consent has the potential to
maximize the use of human biological resources accord-
ing to the requirements of many funders as illustrated
in Figure 1. Third, bridging consent allows economies of
DSCR
DSBR PBR
Meta-Analysis
DSCR returns 
DS results, 
enriches DSBR
DSCR, DSBR and PBR use data and samples 
for meta-analysis
DSCR returns 
results to 
PBR
DSBR feed 
DSCR with 
data and 
samples
PBR serves DSCR 
for stratification, 
validation,
replication and 
controls purposes
Figure 1 Bridging consent: The lift bridge.
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across their research programs. Finally, bridging consent
may promote greater transparency around data sharing
practices which are often made possible through e.g.
Research Ethics Committees approval without the
research participants’ knowledge [3,36]. While largely
applicable to the use of previously collected samples and
data, the bridging of consents is the first part of a new
scheme proposing a more flexible approach to the use
of data collections in different research domains. How-
ever, a complete integration of research domains will
probably require the creation of an international code of
conduct for data sharing across research domains.
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